Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study
NCT07215624 · View on ClinicalTrials.gov ↗
Study Summary
This study evaluates the use of extended venous thromboembolism prophylaxis (ePPx) following abdominopelvic cancer surgery within the NCI Community Oncology Research Program (NCORP) network, targeting surgeons and surgical advanced practice providers (APPs).
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (20)
Iowa
- Mercy Hospital — Cedar Rapids
- Oncology Associates at Mercy Medical Center — Cedar Rapids
- Blank Children's Hospital — Des Moines
- Mercy Medical Center - Des Moines — Des Moines
- Iowa Lutheran Hospital — Des Moines
Delaware
- Helen F Graham Cancer Center — Newark
- Medical Oncology Hematology Consultants PA — Newark
- Christiana Care Health System-Christiana Hospital — Newark
Georgia
- Northside Hospital — Atlanta
- Augusta University Medical Center — Augusta
- Northside Hospital - Gwinnett — Lawrenceville
Michigan
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor
- Chelsea Hospital — Chelsea
- Trinity Health Saint Mary Mercy Livonia Hospital — Livonia
Minnesota
- Sanford Joe Lueken Cancer Center — Bemidji
- Essentia Health Saint Joseph's Medical Center — Brainerd
Arkansas
- Mercy Hospital Fort Smith — Fort Smith
Illinois
- Carle Cancer Center — Urbana
Maine
- MaineHealth Maine Medical Center- Scarborough — Scarborough
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2026-01-15 |
| Est. Completion | 2027-06-01 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07215624
The ClinicalTrials.gov registry entry for NCT07215624 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,061 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Malignant Female Reproductive System Neoplasm appearing as the primary indexed condition, and to 1 intervention — of which Non-Interventional Study is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07215624 reports 20 study locations spanning 9 distinct geographic areas — top geographies include Iowa, Delaware, Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07215624 about?
NCT07215624 is a clinical study titled "Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study". This study evaluates the use of extended venous thromboembolism prophylaxis (ePPx) following abdominopelvic cancer surgery within the NCI Community Oncology Research Program (NCORP) network, targeting surgeons and surgical advanced practice providers (APPs).
What is the current status of trial NCT07215624?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2026-01-15. Estimated completion is 2027-06-01.
What conditions does trial NCT07215624 study?
This clinical trial studies the following conditions: Malignant Female Reproductive System Neoplasm, Malignant Digestive System Neoplasm, Malignant Genitourinary System Neoplasm. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07215624?
The interventions under investigation include: Non-Interventional Study (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07215624?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,061 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07215624 being conducted?
This trial has 20 study locations across Arkansas, Delaware, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.